EL7.AI
Mergers & AcquisitionsMedium•9 November 2026•
3 min read

Record €7.58 Billion Financing Supports CVC’s Acquisition of Recordati

Key Facts

1The financing package supporting CVC’s acquisition of Recordati amounted to the equivalent of €7.58 billion.
2The multi-currency senior secured bond issue was valued at the equivalent of €6.05 billion, with maturities in 2031 and 2033.
3The source described the deal as the largest leveraged buyout announced in Europe since the start of 2026.
4The consortium secured 74.3% of Recordati’s shares at the end of the original offer period, exceeding the 66.7% acceptance threshold and remaining below the 90% delisting threshold.

White & Case announced on November 6, 2026, a financing package equivalent to €7.58 billion to support the acquisition of Italian company Recordati by a consortium led by CVC and take it private. The law firm described it as senior secured financing that also includes a PIK component, or payment-in-kind. It said the deal is the largest leveraged buyout announced in Europe since the start of 2026. It described the senior secured bond issue as the largest ever by a European issuer in the B rating category. The size of the financing puts the borrowing arrangements at the center of the acquisition, whose offer entered a follow-on phase after the consortium exceeded the minimum acceptance threshold without reaching the percentage required to delist the company.

The financing includes a multi-currency senior secured bond issue by Respighi HoldCo, with a value equivalent to €6.05 billion. The tranches comprise €4.450 billion of fixed- and floating-rate notes across three tranches, in addition to $1.790 billion of fixed-rate dollar notes across two tranches. The tranches mature in 2031 and 2033, according to White & Case. The bond issue is part of the total financing package of €7.58 billion, not the whole package. The deal structure also distinguishes between senior secured bridge facilities and the bond issue, while the guarantee facility is valued at €11 billion.

The financing matters because of its connection to the stages of the offer for Recordati, not just the amount borrowed. Reuters said the revised offer price represented a 16.6% premium to the share price at the close on March 25, 2026, the last trading day before the announcement of non-binding interest in the acquisition. When the original offer period ended on October 23, the consortium had secured 74.3% of the shares. That stake exceeded the minimum acceptance threshold of 66.7% but remained below the 90% required to delist the company, according to Reuters. This means the offer achieved the minimum acceptance threshold, while the consortium had not reached the delisting threshold by the end of the original period.

Reuters said the vehicle may seek to merge Recordati if the consortium’s stake does not reach 90%, a route that could leave minority shareholders holding shares in an unlisted company. This provides context for the financing of the company’s move to private ownership, with the position of shareholders not covered by the offer still tied to the eventual ownership structure. Recordati is headquartered in Milan and operates globally in drug development and marketing. Its activities also include a specialty business in treatments for rare diseases, according to White & Case. The company employs more than 4,700 people, the same statement said.